Announcement – New Cancer Center Opening at 8613 Lee Highway, Fairfax, Virginia, 22031: The Fairfax office previously located at 8503 Arlington Blvd, Suite 400, has RELOCATED as of April 13th 2021. (Entrance is around on the side – the side not facing Lee Highway) – see here

COVID19 Update: All VCS sites will be conducting temperature checks for all patients and visitors at entrances. For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine are available for routine office visits. More Information-PLEASE CLICK HERE

Molecular Tumor Board - Personalized Medicine Virginia Cancer Specialists

Virginia Cancer Specialists (VCS) Molecular Tumor Board

The Virginia Cancer Specialists Precision or Personalized Medicine Molecular Tumor Board is a resource for our multidisciplinary cancer team working together and sharing clinical decisions – studying the molecular attributes of our patients’ tumors with a panel of experts.   This will help optimize our patients’ treatments but also identify appropriate clinical trials at the Virginia Cancer Specialists (VCS) Research Institute or with our partners throughout the US.

“The Virginia Cancer Specialists Tumor Board is charged with the optimizing the care of our patients, both with standard treatments as well as novel clinical trials” Dr. Alex Spira, MD, PhD, FACP

Personalized or “Precision” Medicine

What is precision oncology or personalized medicine in cancer care? It is a targeted approach to cancer treatment, which allows the physician to utilize treatments for patients based on a genetic study of their disease. This type of targeted therapy uses information “the molecular profile” of a tumor to assist in deciding which care or treatment will provide the best outcome for a patient.

Personalized medicine for cancer applies molecular diagnostic testing, including DNA sequencing, to identify cancer-driving irregularities in a cancer’s genome. It uses targeted drugs and immunotherapies engineered to directly attack the cancer cells with specific abnormalities, leaving normal cells largely unharmed. By defining the consequences of these genetic irregularities physicians can identify specific therapies directed against each genetic abnormality for each individual patient’s unique DNA profile.

Once a genetic irregularity is identified, a specific targeted treatment can be designed to attack a specific mutation or other cancer-related change in the DNA programming of cells. This targeted therapy is developed to treat only the cancer cells and minimize damage to normal, healthy cells. Cancer treatments that “target” cancer cells may offer the advantage of reduced treatment-related side effects.

Cancer patients should discuss the role of genomic biomarker testing with their oncologist/physician to determine whether a specific precision cancer medicine or immunotherapy is available to treat their individual cancer. Testing can also reveal specific genetic mutations where new precision medicines are being developed in clinical trials.